View Cart  

Panel Lacks Consensus on Surrogate Endpoint for Aspirin Alternative

An FDA advisory panel could not reach a consensus on whether an effect on bypass graft failure could be used as an approvable trial endpoint for thromboxane receptor antagonists (TBAs) as an aspirin alternative for coronary artery bypass graft (CABG) patients.

To View This Article:


Subscribe To Drug Industry Daily